Smith & Nephew

Smith & Nephew plc engages in the development, manufacture, marketing, and sale of medical devices. It operates through the following segments: Orthopaedics; Sports Medicine and ENT; and Advanced Wound Management. The Orthopaedics and Sports Medicine and ENT segment consists of the following businesses: knee implants, hip implants, other reconstruction, trauma, sports medicine joint repair, arthroscopic enabling technologies and ENT. The Advanced Wound Management segment comprises advanced wound care, advanced wound bioactives and advanced wound devices businesses. The company was founded by Thomas James Smith in 1856 and is headquartered in Watford, the United Kingdom.

Earnings data Q4 2019

Smith & Nephew plc engages in the development, manufacture, marketing, and sale of medical devices. It operates through the following segments: Orthopaedics, Sports Medicine and ENT, and Advanced Wound Management. The Orthopaedics and Sports Medicine and ENT segment consists of the following businesses: knee implants, hip implants, other reconstruction, trauma, sports medicine joint repair, arthroscopic enabling technologies, and ENT. The Advanced Wound Management segment includes advanced wound care, advanced wound bioactives, and advanced wound devices businesses. The company was founded in 1856 and is headquartered in Watford, the United Kingdom.

State-of-the-art centre to focus on digital and robotic surgery LONDON, Nov. 9, 2021 /PRNewswire/ -- Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology business, today announces its first dedicated Medical Education Centre to support customers across the Asia Pacific region. Strategically located in Singapore, the centre will support the safe and effective use of Smith+Nephew's products as well as the professional development of healthcare professionals across the region.

Smith+Nephew establishes its first Medical Education Centre for the Asia Pacific region in Singapore

Smith & Nephew is 165 years old, highly adaptable, and will likely outlive us all. And our grandchildren. SNN has paid dividends on its ordinary shares every year since 1937.

Smith & Nephew Is A Premium Brand That Should Deliver Something Special

Smith & Nephew PLC (LSE:SN) said it expects its full-year results to come in at the low end of guidance, after the impact of the COVID-19 Delta variant and supply chain disruptions hit revenue in its Orthopaedics business. The company said it is implementing a range of actions to address the supply chain challenges.

Smith & Nephew sees full-year performance at low end of guidance on impact from Delta variant and supply chain issues

LONDON, Nov. 2, 2021 /PRNewswire/ -- Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology business, today announces the introduction of its LEGION CONCELOC Cementless Total Knee System (TKS) and first completed surgical procedures.  CONCELOC Advanced Porous Titanium is a patented, proprietary, 3D printed porous structure technology first used in Smith+Nephew's leading REDAPT™  Revision Hip System, launched in 2016.

Smith+Nephew introduces the LEGION™ CONCELOC™ Cementless Total Knee System with proprietary 3D printed Advanced Porous Titanium technology

LONDON, Oct. 26, 2021 /PRNewswire/ -- Smith+Nephew (NYSE:SNN; LSE:SN), the global medical technology business, is pleased to announce the results of a systematic review and meta-analysis of comparative trials to determine the efficacy of its IODOSORB 0.9% Cadexomer Iodine Range* on chronic wounds versus standard care specific to the wound type.1 The review found that wounds were more than twice as likely to completely heal with IODOSORB Range than with standard care, and significantly greater reductions in wound area** were observed after 8 weeks of treatment versus standard care. Use of IODOSORB Range helped reduce barriers to healing such as exudate, slough, pus, debris and bacteria, significantly reducing wound area** and increasing the chance of healing chronic wounds compared with standard care.1 Venous leg ulcers (VLUs), diabetic foot ulcers (DFUs) and pressure ulcers were included in the study.

Smith+Nephew's IODOSORB™ Range shown more than twice as likely to heal wounds than standard care

Smith & Nephew PLC shares represent a “rare value opportunity”, according to a leading investment bank that has reiterated its bullish stance on and price target for stock in the medical devices giant. Credit Suisse reckons November 4's trading update could act as a catalyst for the price, though it admits there may also be some pressures – including price and technology pressures and dilutive M&A.

Smith & Nephew shares represent a “rare value opportunity”, according to a leading investment bank

Smith+Nephew (SNN) introduced the RI.HIP NAVIGATION software on the CORI Surgical System and announced the commercial availability of RI.INSIGHTS at the AAOS 2021 Annual Meeting.

Smith+Nephew (SNN) Releases New Features for Hip Arthroplasty

LONDON , Sept. 1, 2021 /PRNewswire/ -- Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology business, today announces the introduction of two significant new technologies to its total knee arthroplasty (TKA) portfolio - the JOURNEY II Medial Dished (MD) for TKA and SYNC Performance Instruments.

Smith+Nephew introduces pioneering new technologies for its JOURNEY™ II total knee arthroplasty portfolio

LONDON , Sept. 1, 2021 /PRNewswire/ -- Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology business, today announces significant enhancements to its Real Intelligence digital ecosystem and surgical robotics programs at the American Academy of Orthopaedic Surgeons (AAOS) 2021 Annual Meeting in San Diego.

Smith+Nephew to expand Real Intelligence digital ecosystem and CORI™ Surgical System with total hip arthroplasty

LONDON, Aug. 31, 2021 /PRNewswire/ -- Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology business, today announces it will feature its recently expanded Extremities portfolio at the American Academy of Orthopaedic Surgeons 2021 Annual Meeting being held in San Diego, CA. The exciting new portfolio is the result of acquiring the Extremity Orthopaedics business of Integra LifeSciences earlier in 2021, and includes solutions for upper and lower extremity arthritis, and fracture management of the shoulder, elbow, wrist, hand, foot and ankle.

Smith+Nephew launches new total ankle and total shoulder replacement technologies; showcases recently acquired Extremity Orthopaedics portfolio at AAOS

LONDON, Aug. 31, 2021 /PRNewswire/ -- Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology business, today announces it will showcase meaningful new material evidence for its OR3O Dual Mobility Hip System and OXINIUM DH Technology at the American Academy of Orthopedic Surgeons (AAOS) 2021 Annual Meeting in San Diego, CA. New data confirms a reduction in material loss and corrosion for OXINIUM DH (Diffusion Hardened) liners used with the OR3O System – an improvement on equivalent CoCr dual mobility liners within the test.1 In-vitro testing showed a substantial (p

New data underscores material benefits of Smith+Nephew's OXINIUM™ DH Technology and OR3O™ Dual Mobility System for total hip arthroplasty versus Cobalt Chrome liners

LONDON, Aug. 30, 2021 /PRNewswire/ -- Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology business, today announces it will showcase its latest Sports Medicine innovations for joint repair and arthroscopic enabling technologies during the American Academy of Orthopaedic Surgeons 2021 Annual Meeting being held in San Diego, CA. The latest technologies include: FAST-FIX™ FLEX Meniscal Repair System: The only device to offer a surgeon-guided, bendable needle and shaft providing access to all zones of the meniscus.

Smith+Nephew to feature new Sports Medicine technology for joint repair and connected arthroscopic tower during AAOS 2021 Annual Meeting

LONDON, Aug. 30, 2021 /PRNewswire/ -- Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology business, today announces its proprietary OXINIUM (Oxidized Zirconium) Technology has established itself as the best performing bearing with the lowest risk of revision in total hip arthroplasty (THA)1-4, alongside similarly strong clinical performance in knees.5 These results are substantiated by four national and regional joint registries1-4 over the last 20 years with more than 2 million procedures4 to draw from. Through a unique manufacturing process, the zirconium alloy material transforms and hardens through oxidation.

Smith+Nephew's OXINIUM™ Technology recognized as the best performing bearing with lowest risk of revision in total hip arthroplasty

LONDON, Aug. 17, 2021 /PRNewswire/ -- Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology business, today announces the launch of WEREWOLF FASTSEAL 6.0 Hemostasis Wand, bringing its leading radio-frequency technology to orthopaedic reconstruction surgeons. Using low temperature thermal energy, the FASTSEAL 6.0 Hemostasis Wand delivers hemostatic sealing during open orthopaedic procedures such as total joint arthroplasty (TJA) – this technology has shown to significantly reduce total blood loss*1 as well as significantly shortening procedure time.

Smith+Nephew expands its leading WEREWOLF™ Technology into total joint arthroplasty with launch of WEREWOLF FASTSEAL 6.0 Hemostasis Wand

Smith & Nephew plc (SNN) CEO Roland Diggelmann on Q2 2021 Results - Earnings Call Transcript

Smith & Nephew Plc (NYSE: SNN) revenues soared in Q2 as COVID-19 restrictions eased and levels of elective surgery returned towards normal in many markets. The Company reported revenues of $1.3 billion, up 48.2%, with underlying growth of 40.3%.

Smith & Nephew Stock Is Trading Lower Despite Posting Surge In Q2 Revenues, Profit

LONDON, July 21, 2021 /PRNewswire/ -- Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology business, today announces study results showing patients treated with just its REGENETEN Bioinductive Implant for partial-thickness rotator cuff tears (>3mm) experienced significantly improved shoulder function during early recovery compared to patients receiving a REGENETEN Implant plus traditional surgical repair, with equivalent efficacy at one year.1   Presented at the AOSSM-AANA Combined 2021 Annual Meeting, study investigators compared the use of a REGENETEN Implant alone (without surgical repair) to a REGENETEN Implant plus traditional surgical repair for the treatment of partial-thickness rotator cuff tears in 227 patients across 19 US surgical centers. Key findings of the study included: Compared with traditional surgical repair, patients reported a significant improvement in shoulder function in the early post-operative period (weeks 2 and 6) with the REGENETEN Implant alone Treatment with the REGENETEN Implant alone demonstrated equivalent efficacy to REGENETEN plus traditional surgical repair with minimal revisions across both treatment groups at 1 year Among all patients receiving a REGENETEN Implant, patients reported significant improvements in pain, function and quality of life from at 1 year compared with pre-surgery values "The results of this pioneering study show that using REGENETEN alone simplifies the surgical procedure.

Study shows Smith+Nephew's REGENETEN™ Bioinductive Implant sets new standard of recovery for partial-thickness rotator cuff tears

Smith+Nephew's (SNN) FAST-FLIX FLEX Meniscal Repair System to provide long-term benefits to patients.

Smith+Nephew's (SNN) New Device to Boost Patient Outcomes

LONDON, July 7, 2021 /PRNewswire/ -- Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology business, today announces the launch of its FAST-FIX FLEX Meniscal Repair System, the only device to offer a surgeon-guided, bendable needle and shaft providing access to all zones of the meniscus. Improving access leads to a greater opportunity to repair the meniscus rather than remove it, resulting in long-term benefits to the patient.1-3, 13-15   Building on the 15-year clinical legacy of its FAST-FIX platform, Smith+Nephew's new FAST-FIX FLEX system uses an all-inside approach which may eliminate the need for further incisions, reduce the risk of neurovascular injury, and provide procedural efficiency to support faster operating times.4 The added ability to bend both the needle and shaft enables surgeons access to the mid-body and anterior zones, inaccessible by previous FAST-FIX devices.

Smith+Nephew launches the FAST-FIX™ FLEX Meniscal Repair System; extends all-inside repair possibilities with greater access across all zones of the meniscus*

Smith & Nephew PLC's (LON:SN) growth drivers are “underappreciated” according to analysts at Credit Suisse, who have upgraded the stock to ‘outperform' from ‘neutral' and upped their target price to 1,805p from 1,560p. In a note on Wednesday, the bank said investors “underestimate the combined power of recently-acquired growth drivers with corresponding return leverage mid term” and that they expected the medical equipment group's stock to “reverse its material underperformance over the past 12 months”.

Smith & Nephew growth drivers underappreciated, says Credit Suisse

LONDON, May 5, 2021 /PRNewswire/ -- Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology business, today announces the launch of ARIA Home PT, a remote physical therapy product as part of the ARIA suite of solutions. ARIA Home PT offers a customized experience for patients on their time and in their home, while still providing relevant actionable data for clinicians, by leveraging advanced technology, telehealth solutions from licensed physical therapists (PTs) and digital avatar-based guidance.

Smith+Nephew launches ARIA Home PT - a remote physical therapy solution

LONDON, April 30, 2021 /PRNewswire/ -- Smith+Nephew (NYSE:SNN; LSE:SN), the global medical technology business, announces the publication of new research showing that clinicians estimated that 45% of their patients with chronic wounds would benefit from greater involvement in their care, and half of these clinicians believed this would enable them to spend more time with other patients.1 The results of the research, published in Wounds International, concluded that the COVID-19 pandemic had been instrumental in providing a real-world opportunity for clinicians to better understand the benefits of greater patient shared care. Clinicians reported a decline in home visits and an increase in remote care via digital communication tools such as video calls, text and email.1 They also claimed to have used alternative dressings or therapies that reduced the frequency of dressing changes.1 Some expressed a concern that when patients are involved in their care they don't change the wound dressing at the right frequency.2 Advanced features such as absorbency and exudate management, present in Smith+Nephew's ALLEVYN LIFE Dressings, were rated as most important when choosing a foam.2 Practitioner attitudes towards encouraging shared care varied globally; in China, the UK and the USA, shared care is a more established approach than in France and Germany, where care is predominately nurse-led.

Smith+Nephew sponsored research shows COVID-19 has accelerated patient involvement in chronic wound care which can be supported by advanced foams such as ALLEVYN™ LIFE Dressing

Smith & Nephew PLC (LON:SN.) reinstated full-year guidance as visibility is improving thanks to the COVID-19 vaccine rollout programmes and healthcare systems reopening to non-urgent surgery.

Smith & Nephew sees the light at the end of the tunnel

LONDON, April 28, 2021 /PRNewswire/ -- Smith+Nephew (LSE: SN, NYSE: SNN), the global medical technology business, today announces a new study showing that computer-guided technology for total hip arthroplasty (THA) – such as Smith+Nephew's RI.HIP NAVIGATION – significantly reduces the risk of revision and increases patient satisfaction when using Smith+Nephew implants. The study is the first of its kind using the dataset from the world's largest arthroplasty register (National Joint Registry of England, Wales and Northern Ireland) to investigate the effect of computer-guided THA surgery on implant survivorship.1 The data reported on THA surgery performed using Smith+Nephew hip replacement components implanted for osteoarthritis since 2003.

Computer-guided surgery with Smith+Nephew's hip replacement implants shown to significantly improve survivorship and increase patient satisfaction compared to conventional surgery

LONDON, April 20, 2021 /PRNewswire/ -- Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology business, today announces new enabling technologies for its INTELLIO™ Connected Tower Solution with the introduction of the DOUBLEFLO™ Inflow/Outflow Pump* and 4KO™ (Optimized) Arthroscopes and Laparoscopes. Designed to be simple, effective and connected, the DOUBLEFLO Pump** is able to respond to a surgeon's needs in diverse clinical situations1,2.

News for Smith & Nephew Stock (SNN)